WP
JNCE

Woodline Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Woodline Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,359,528
Closed -$11.4M – 875
2021
Q4 		$11.4M Buy
+1,359,528
New +$11.2M 0.16% 176
2021
Q1 		– Sell
-940,902
Closed -$6.59M – 488
2020
Q4 		$6.59M Buy
940,902
+11,251
+1% +$87.6K 0.17% 144
2020
Q3 		$7.59M Buy
+929,651
New +$5.76M 0.25% 101

Other funds holding JNCE

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Woodline Partners's JNCE Position: Q1 2022 in Review

Woodline Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 1,359,528 shares — an estimated $11.4M sold.

Woodline Partners first reported a position in JNCE in Q3 2020 and held it in 3 quarters. The position peaked at $11.4M in Q4 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Woodline Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Woodline Partners sold 1,359,528 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $11.4M.
  • Woodline Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Woodline Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $11.4M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Woodline Partners's 13F filing for Q1 2022, filed 16 May 2022.